Our prospective NPC screening study showed that the anti-EBV IgA test could improve early diagnostic rate (79.0% for the screened participants versus 22.4% for the non-screened participants) and decrease NPC mortality (1.8 per 100 000 person-year for the screened participants versus 8.3 per 100,000 person-year for the non-participants)12,17. Here, CD79A is linked to nasopharyngeal carcinoma.